Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Conzip

Drug and asset intelligence for Conzip with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
1
Stage
Development stage unavailable

Sponsor company

Cipher Pharmaceuticals →

Recent signals(2)

RegulatoryJune 26, 2026

FDA Accepts Supplemental NDA for Conzip by Cipher Pharmaceuticals

The FDA has accepted a supplemental NDA for Conzip, which contains tramadol hydrochloride.

RegulatoryJune 26, 2026

FDA Approves Supplemental Application for CONZIP (Tramadol Hydrochloride)

The FDA has approved a supplemental application for CONZIP, which contains tramadol hydrochloride.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Cipher Pharmaceuticals — Conzip

Monitor the timeline for the FDA's final decision and any subsequent market entry strategies from Cipher Pharmaceuticals.

June 26, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Opioid →
Pain Management →
Pain Management · Opioid →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.